Jul 12, 2020
MediSieve Celebrates International Women In Engineering Day
Dr Cristina Blanco-Andujar shared her thoughts on the importance of gender diversity in engineering.
June 23 is an annual awareness campaign for the International Women in Engineering Day (IENWED) organised by the Royal Academy of Engineering. MediSieve’s CTO, Dr Cristina Blanco-Andujar, shared her thoughts on the importance of gender diversity in engineering and how it has benefited MediSieve.
The campaign aims to celebrate and raise awareness about women in engineering and encourages more people to consider equal opportunities for all within the profession. The theme in 2020 was #ShapeTheWorld highlighting the vital role of women in finding solutions to global problems by bringing fresh, diverse and inclusive ideas. MediSieve’ CTO, Dr Cristina Blanco-Andujar, joined the conversation and talked about the potential benefits of the MediSieve’s technology. She shared that, "The technology has the potential to bring benefit not only to patients but also to clinicians all over the world... knowing that what you do can make a difference in people’s lives is all you need to keep going.”
MediSieve is inclusive of all genders and has a diverse team. This enables the company to see situations from different points of view, leading to ideas and insights which would otherwise be missed.
More about the campaign:
About Magnetic Blood Filtration
MediSieve's Magnetic Blood Filtration Platform is intended to enable the rapid and specific depletion of specific agents from the bloodstream of patients. The extracorporeal therapy uses therapeutic Magnetic Beads that are designed to bind specifically to the clinical target. The Beads are introduced into the extracorporeal circuit during the therapy, mixing with the patient’s blood and binding to the clinical targets. The Delivery Platform captures all the Magnetic Beads and bound targets, preventing their return to the patient.
MediSieve is a London-based BioTech start-up that has developed Magnetic Blood Filtration, a revolutionary platform therapy that enables the physical removal of specific substances from the bloodstream of patients. It can be used (1) as a direct treatment, (2) to increase the safety and efficacy of other therapies, or (3) to enable personalised medicine. The company is a spin-off from University College London and is developing its products at the White City Innovation District in West London. MediSieve is actively seeking investment and partnerships.
INVESTOR AND PARTNERSHIP CONTACT: